Effect of guselkumab on serum biomarkers in patients with active psoriatic arthritis and inadequate response to tumor necrosis factor inhibitors: results from the COSMOS phase 3b s... by Schett, Georg, Chen, Warner, Gao, Sheng, Chakravarty, Soumya D, Shawi, May, Lavie, Frederic, Zimmermann, Miriam, Sharaf, Mohamed, Coates, Laura C, Siebert, Stefan

Get full text

Correction: Effect of guselkumab on serum biomarkers in patients with active psoriatic arthritis and inadequate response to tumor necrosis factor inhibitors: results from the COSMO... by Schett, Georg, Chen, Warner, Gao, Sheng, Chakravarty, Soumya D, Shawi, May, Lavie, Frederic, Zimmermann, Miriam, Sharaf, Mohamed, Coates, Laura C, Siebert, Stefan

Get full text

Modulation of Interleukin‐23 Signaling With Guselkumab in Biologic‐Naive Patients Versus Tumor Necrosis Factor Inhibitor–Inadequate Responders With Active Psoriatic Arthritis by Siebert, Stefan, Coates, Laura C., Schett, Georg, Raychaudhuri, Siba P., Chen, Warner, Gao, Sheng, Seridi, Loqmane, Chakravarty, Soumya D., Shawi, May, Lavie, Frederic, Sharaf, Mohamed, Zimmermann, Miriam, Kollmeier, Alexa P., Xu, Xie L., Rahman, Proton, Mease, Philip J., Deodhar, Atul

Get full text

Effect of guselkumab on serum biomarkers in patients with active psoriatic arthritis and inadequate response to tumor necrosis factor inhibitors: results from the COSMOS phase 3b s... by Schett, G, Chen, W, Gao, S, Chakravarty, SD, Shawi, M, Lavie, F, Zimmermann, M, Sharaf, M, Coates, LC, Siebert, S

Get full text

Guselkumab, a Selective Interleukin‐23 p19 Subunit Inhibitor, Resolves Dactylitis in Patients With Active Psoriatic Arthritis: Pooled Results Through Week 52 From Two Phase 3 Studi... by McGonagle, Dennis, McInnes, Iain B., Deodhar, Atul, Schett, Georg, Shawi, May, Chakravarty, Soumya D., Kollmeier, Alexa P., Xu, Xie L., Sheng, Shihong, Xu, Stephen, Ritchlin, Christopher T., Rahman, Proton, Mease, Phillip J.

Get full text

Serious infections in patients with self-reported psoriatic arthritis from the Psoriasis Longitudinal Assessment and Registry (PSOLAR) treated with biologics by Ritchlin, Christopher T, Stahle, Mona, Poulin, Yves, Bagel, Jerry, Chakravarty, Soumya D, Kafka, Shelly, Srivastava, Bhaskar, Langholff, Wayne, Gottlieb, Alice B

Get full text

A Common Pharmacophore for Cytotoxic Natural Products That Stabilize Microtubules by Ojima, Iwao, Chakravarty, Subrata, Inoue, Tadashi, Lin, Songnian, He, Lifeng, Horwitz, Susan Band, Kuduk, Scott D., Danishefsky, Samuel J.

Get full text

A Novel Approach to the Study of Solution Structures and Dynamic Behavior of Paclitaxel and Docetaxel Using Fluorine-Containing Analogs as Probes by Ojima, Iwao, Kuduk, Scott D, Chakravarty, Subrata, Ourevitch, Michèle, Bégué, Jean-Pierre

Get full text

(Dipropylphenoxy)phenylacetic acids: a new generation of nonpeptide angiotensin II receptor antagonists by Dhanoa, Daljit S, Bagley, Scott W, Chang, Raymond S. L, Lotti, Victor J, Chen, Tsing Bau, Kivlighn, Salah D, Zingaro, Gloria J, Siegl, Peter K. S, Chakravarty, Prasun K

Get full text

Quinazolinone Biphenyl Acylsulfonamides: A potent new class of angiotensin-II receptor antagonists by Chakravarty, Prasun K., Strelitz, Robert A., Chen, Tsing-Bau, Chang, Raymond S.L., Lotti, Victor J., Zingaro, Gloria J., Schorn, Terry W., Kivlighn, Salah D., Siegel, Peter K.S., Patchett, Arthur A., Greenlee, William J.

Get full text

Triazolinones as nonpeptide angiotensin II antagonists. 2. discovery of a potent and orally active triazolinone acylsulfonamide by Chang, L.L., Ashton, W.T., Flanagan, K.L., Naylor, E.M., Chakravarty, P.K., Patchett, A.A., Greenlee, W.J., Bendesky, R.J., Chen, T.-B., Faust, K.A., Kling, P.J., Schaffer, L.W., Schorn, T.W., Zingaro, G.J., Chang, R.S.L., Lotti, V.J., Kivlighn, S.D., Siegl, P.K.S.

Get full text